Special Issue

Gut–Brain Axis and Diabetes

Message from the Guest Editor

Bidirectional communication along the gut–brain axis is fundamental in health and diseases. This close and sensitive relationship between the gastrointestinal system and brain is greatly affected in diabetes. Gastrointestinal symptoms or neuronal-damage-affected central and peripheral nervous systems are common in diabetic patients. Diabetic microbial dysbiosis, chronic low-grade inflammation, and immune responses have critical roles in modulating the gut–brain axis. Gut-derived bacterial metabolites trigger the neuro-inflammatory processes in the enteric nervous system and modulate the brain functions. Gut hormones secreted by enteroendocrine cells are also able to activate the enteric, spinal, or vagal nerve endings, creating critical links among them. The aim of this Special Issue is to highlight the effects of diabetes on critical elements of the gut–brain axis influencing both gastrointestinal and brain functions. This Special Issue is open for original research articles as well as review articles.

Guest Editor

Dr. Nikolett Bódi

Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary

Deadline for manuscript submissions

31 October 2025

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/236165

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).